Professor of Medicine
Beth Israel Deaconess Medical Center
United States of America
Manuel Hidalgo-Medina, M.D., is a Professor of Medicine at Beth Israel Deaconess Medical Center in Boston. He went to medical school at Universidad de Navarra and completed his residency at Hospital Doce de Octubre, with a fellowship at University of Texas Health Science Center.
Nogova L, Sequist LV, Perez Garcia JM, Andre F, Delord JP, Hidalgo M, Schellens JH, Cassier PA, Camidge DR, Schuler M, Vaishampayan U. Evaluation of BGJ398, a fibroblast growth factor receptor 1-3 kinase inhibitor, in patients with advanced solid tumors harboring genetic alterations in fibroblast growth factor receptors: results of a global phase I, dose-escalation and dose-expansion study. Journal of Clinical Oncology. 2016 Nov 21;35(2):157-65.
Lieu CH, Hidalgo M, Berlin JD, Ko AH, Cervantes A, LoRusso P, Gerber DE, Eder JP, Eckhardt SG, Kapp AV, Tsuhako A. A Phase Ib Dose‐Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS. The Oncologist. 2017 Jun 7:theoncologist-2017.
Delord JP, Robert C, Nyakas M, McArthur GA, Kudchakar R, Mahipal A, Yamada Y, Sullivan RJ, Arance A, Kefford RF, Carlino MS. Phase I Dose-Escalation and-Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma. Clinical Cancer Research. 2017 Jan 1:clincanres-2923.